Glossary

Urothelium/Urothelial Cells:
The specialized tissue lining the inside of the bladder, ureters, and renal pelvis. Most cancers in the urinary tract start in these cells.
Renal Pelvis:
The funnel-shaped area inside the kidney where urine collects before draining into the ureter. One of the two locations where UTUC originates.
Ureter:
The tube that carries urine from the kidney down to the bladder. The other location where UTUC can develop.
Lymph Nodes:
Small, bean-shaped organs throughout the body that filter fluid and help fight infection. Cancer spreading to lymph nodes is a major turning point—in UTUC, any lymph node involvement places a patient at Stage IV.
Metastasis/Metastatic:
Cancer that has spread from its original site to distant organs (lungs, liver, bone). Metastatic disease is the most advanced stage and the hardest to treat.
Recurrence:
Cancer that comes back after treatment. Can be local (same area), regional (nearby lymph nodes), or distant (metastatic). Predicting recurrence is the central goal of ctDNA research.
Micrometastasis:
Tiny clusters of cancer cells that have spread beyond the original tumor but are too small to detect with standard imaging. Liquid biopsy (ctDNA) may be able to detect these before they grow.
Histology/Variant Histology:
The study of tissue under a microscope. “Variant histology” means the cancer contains unusual cell types beyond standard urothelial cells, which can affect how aggressively it behaves and how it responds to treatment.
High-Grade vs. Low-Grade:
A measure of how abnormal cancer cells look under a microscope. High-grade cells grow and spread faster; low-grade cells are slower and less aggressive. 65% of UTUC is high-grade at diagnosis.
Multifocal:
Cancer found in more than one location at the same time, which increases recurrence risk and affects treatment planning.
Calyceal Diverticulum:
A small pouch or outpouching in the kidney’s collecting system where the wall is thin. Kidney stones can lodge here, and the thin wall means cancer can invade through more easily. A known but often under-flagged risk factor for UTUC.
Lynch Syndrome:
An inherited genetic condition caused by mutations in DNA mismatch repair genes. Significantly increases the risk of UTUC and several other cancers.

UTUC (Upper Tract Urothelial Carcinoma):
Cancer of the lining of the renal pelvis or ureter. About 7% of kidney cancers. Shares cell type with bladder cancer but differs in behavior, genetics, and treatment response.
RCC (Renal Cell Carcinoma):
The most common kidney cancer (~90%), originating in the kidney’s filtering tubes. Biologically distinct from UTUC—different treatments, different research.
Urothelial Carcinoma (UC):
The broader category of cancers arising from urothelial cells, encompassing both bladder cancer and UTUC. Most clinical trials enroll “UC” patients but are dominated by bladder cancer.
Muscle-Invasive:
Cancer that has grown into the muscle wall (T2 or higher). A critical threshold—once cancer invades muscle, prognosis worsens and more aggressive treatment is needed.
TNM Staging (T, N, M):
The system used to describe how far cancer has spread. T = tumor depth (T1–T4), N = lymph node involvement (N0–N2), M = distant metastasis (M0–M1). These combine into an overall stage (I–IV).
Downstaging:
When treatment before surgery shrinks the cancer to a less advanced stage—e.g., a T3 tumor becoming T1 after chemotherapy. A sign that the treatment is working.
Prognosis:
The likely course and outcome of a disease. In cancer, prognosis is shaped by stage, grade, biomarker status, and treatment response.
Risk Stratification:
The process of sorting patients into groups based on how likely their cancer is to recur or progress. Guides decisions about how aggressively to treat and how closely to monitor.

Biomarker:
A measurable biological signal — a gene mutation, protein, or DNA fragment — that can indicate disease presence, predict outcomes, or guide treatment. ctDNA and PD-L1 are both biomarkers.
ctDNA (Circulating Tumor DNA):
Fragments of tumor DNA that shed into the bloodstream. Detectable via a simple blood draw, ctDNA can signal residual cancer after surgery — often before imaging can detect recurrence.
utDNA (Urinary Tumor DNA)::
Tumor DNA fragments detected in urine. For UTUC patients who commonly develop bladder recurrences, utDNA could offer a less invasive alternative to frequent cystoscopies.
Liquid Biopsy:
A blood or urine test that detects cancer-related signals (like ctDNA) without surgery or tissue removal. Faster, less invasive, and repeatable over time to track disease.
Molecular Residual Disease (MRD):
Cancer that remains after treatment but is too small to see on scans. ctDNA testing is one of the most promising ways to detect MRD and guide treatment decisions.
PD-L1 Expression:
A protein on some tumor cells that helps cancer hide from the immune system. Tumors with high PD-L1 levels tend to respond better to immunotherapy drugs like nivolumab and pembrolizumab.
FGFR3 Alteration:
A mutation in a gene that acts like a growth switch in cells. Found in ~80% of low-grade UTUC and ~36% of metastatic cases — making it a prime target for drugs like erdafitinib and dabogratinib.
Biorepository:
A collection of biological samples (tumor tissue, blood, urine) stored for research.
Companion Diagnostic:
A test approved alongside a specific drug to identify which patients are most likely to benefit. Natera is seeking FDA approval for Signatera as a companion diagnostic based on IMVigor011.
Signatera (Natera):
A personalized, tumor-informed ctDNA test that creates a custom panel from each patient's unique tumor mutations, then monitors blood samples over time to detect recurrence.
eGFR (Estimated Glomerular Filtration Rate)::
A number that estimates how well your kidneys are filtering waste from the blood. The higher the number, the better your kidneys are working. An eGFR of 60 or above is generally considered the threshold for cisplatin eligibility.
Hematuria:
Blood in the urine — the most common presenting symptom of UTUC. Can be visible to the eye (gross hematuria) or detectable only on a lab test (microscopic hematuria).
Nectin-4:
A protein found on the surface of most urothelial cancer cells. It is the target used by enfortumab vedotin (Padcev) to deliver chemotherapy directly to cancer cells and is also being developed as a PET scan tracer for imaging.
HER2:
A protein involved in cell growth that is found on the surface of some cancer cells. The target used by disitamab vedotin, an antibody-drug conjugate being studied in UTUC.

Nephroureterectomy:
Surgery to remove an entire kidney, the ureter, and a small piece of the bladder. The standard treatment for high-risk UTUC — but it permanently reduces kidney function.
Ureteroscopy:
A procedure using a thin scope inserted through the bladder to look inside (and sometimes treat tumors in) the ureter and renal pelvis. Used for diagnosis and for treating low-grade UTUC with laser.
Cystoscopy:
A procedure using a thin camera to examine the inside of the bladder. UTUC patients typically need one every 3 months after surgery to check for bladder recurrence.
Adjuvant Therapy:
Treatment given after surgery to reduce the chance of cancer returning. The POUT trial proved adjuvant chemotherapy works specifically for UTUC.
Neoadjuvant Therapy:
Treatment given before surgery to shrink tumors. Especially important in UTUC because patients lose a kidney during surgery, which can make them unable to tolerate certain chemo drugs afterward.
Platinum-Based Chemotherapy:
A class of chemo drugs (cisplatin, carboplatin) that are the standard backbone for urothelial cancers. Cisplatin is more effective but harder on the kidneys; carboplatin is the alternative when kidney function is reduced.
Cisplatin-Eligible vs. Ineligible:
Whether a patient's kidney function and overall health allow them to receive cisplatin, the most effective platinum chemo. After nephroureterectomy, many UTUC patients become cisplatin-ineligible.
Immunotherapy (Checkpoint Inhibitors):
Drugs that block proteins (PD-1, PD-L1) cancer cells use to hide from the immune system. Examples: nivolumab (Opdivo), pembrolizumab (Keytruda), atezolizumab (Tecentriq).
Antibody-Drug Conjugate (ADC):
A targeted therapy that attaches a chemo drug to an antibody, delivering treatment directly to cancer cells. Enfortumab vedotin (Padcev) is an ADC used in urothelial cancer.
Targeted Therapy:
Drugs that attack cancer cells with specific molecular features (like FGFR3 mutations) while sparing normal cells. Examples: erdafitinib (Balversa), dabogratinib.
Active Surveillance:
A monitoring approach where doctors closely watch a patient's condition through regular testing instead of immediately treating. Used for small, low-risk tumors.
Standard of Care:
The treatment that is widely accepted by doctors as the best available option for a given cancer type and stage. Clinical trials test new treatments against the current standard of care.
JELMYTO (mitomycin gel):
A reverse-thermal gel — liquid when cooled, semi-solid at body temperature — that delivers the chemotherapy drug mitomycin directly to the upper urinary tract. FDA-approved for low-grade UTUC as a kidney-sparing alternative to surgery.
Perioperative Therapy:
Treatment given both before and after surgery, sometimes called "sandwich therapy." Combines the benefits of neoadjuvant and adjuvant approaches.

Phase I / II / III Trial:
Stages of testing a new treatment. Phase I: safety in a small group (~20–100). Phase II: effectiveness and dosing (~100–300). Phase III: comparison against standard of care (~300–5,000+).
Retrospective vs. Prospective Study:
A retrospective study analyzes data that already exists. A prospective study enrolls patients and follows them forward in time. Retrospective studies are faster and cheaper.
Randomized Controlled Trial (RCT):
A study where patients are randomly assigned to treatment or comparison groups, reducing bias. The gold standard of clinical evidence.
Subgroup Analysis:
Looking at results for a specific subset of patients within a larger trial. UTUC patients are often a small subgroup in bladder cancer trials, making UTUC-specific conclusions unreliable.
Disease-Free Survival (DFS):
Time after treatment during which no cancer is detected. A key measure of treatment effectiveness in adjuvant settings.
Overall Survival (OS):
Time from diagnosis or treatment that a patient remains alive. The gold standard outcome measure in cancer research.
Progression-Free Survival (PFS):
Time during which a patient's cancer does not grow or spread. Used especially in metastatic cancer trials where cure is unlikely.
Hazard Ratio (HR):
A number comparing risk between two groups. HR below 1.0 means the treatment group had lower risk. HR 0.55 = a 45% reduction in risk of the event (recurrence or death).
Pathologic Complete Response (pCR):
No detectable cancer in tissue removed during surgery after pre-surgery treatment. A strong signal that treatment worked.
Placebo-Controlled / Open-Label:
Placebo-controlled: patients don't know if they're getting the drug or a dummy treatment. Open-label: everyone knows who's getting what. Each design has tradeoffs in bias vs. practicality.
Cohort:
A defined group of patients in a study who share a characteristic — e.g., "the UTUC cohort" within a larger urothelial cancer trial.
Endpoints (Primary / Secondary):
The outcomes a trial is designed to measure. The primary endpoint is the main question (usually DFS or OS). Secondary endpoints are additional measures like response rate or safety.

IND Application:
Investigational New Drug application — filed with the FDA for permission to begin testing a new treatment in humans. A critical early milestone in the drug development pipeline.
Valley of Death:
The funding gap between early academic research (government-funded) and the proof-of-concept data needed to attract pharma investment. Especially severe for rare diseases like UTUC. Beemok Health Labs operates in this gap.
FDA Approval vs. Off-Label Use:
FDA approval means a drug is proven for a specific condition. Off-label use means prescribing an approved drug for a condition it wasn't specifically tested for — common in UTUC, where approvals are based on bladder cancer trials.
Non-Dilutive Funding:
Money that doesn't require giving up ownership or equity — such as grants, philanthropy, or government awards.
Nivolumab (Opdivo):
An immunotherapy drug (Bristol Myers Squibb) that blocks PD-1. FDA-approved for high-risk urothelial carcinoma after surgery. Tested in CheckMate 274 and CheckMate 901.
Pembrolizumab (Keytruda):
An immunotherapy drug (Merck) that blocks PD-1. Used in combination with enfortumab vedotin (EV+P) in EV-302. Tested in AMBASSADOR for UTUC.
Atezolizumab (Tecentriq):
An immunotherapy drug (Roche) that blocks PD-L1. Tested in IMVigor011 to treat bladder cancer patients who tested positive for ctDNA after surgery.
Enfortumab Vedotin (Padcev):
An antibody-drug conjugate (Seagen/Pfizer, Astellas) that delivers chemo directly to cancer cells. Combined with pembrolizumab, it is now the standard first-line treatment for locally advanced and metastatic urothelial carcinoma.
Erdafitinib (Balversa):
A targeted oral drug (Janssen) that blocks FGFR. Showed particular promise in UTUC patients in the THOR trial — median overall survival of 23.3 months vs. 7.2 months with chemotherapy.
Dabogratinib:
A next-generation FGFR3 inhibitor (Tyra Biosciences) being tested in SURF303 for low-grade UTUC. Designed to be ~25x more selective than earlier FGFR drugs, potentially reducing side effects.
Disitamab Vedotin:
A HER2-targeted antibody-drug conjugate being studied in combination with tislelizumab as adjuvant therapy specifically for UTUC. Early Phase 2 results presented at EAU 2026 showed 97.4% disease-free survival at 12 months.
Tislelizumab:
An immunotherapy drug that blocks PD-1. Being studied in combination with disitamab vedotin as adjuvant therapy for UTUC.